| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911156 | Lung Cancer | 2014 | 7 Pages |
Abstract
We found a higher frequency of EGFR mutations than expected in a cohort with less than 10% never smokers. The outcome after treatment with erlotinib was much better in patients with EGFR mutations than in patients with wild-type EGFR and was independent of performance status and treatment line in EGFR-mutated patients.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Britta Weber, Henrik Hager, Boe S. Sorensen, Tine McCulloch, Anders Mellemgaard, Azza Ahmed Khalil, Ebba Nexo, Peter Meldgaard,